SOAT1 and acute lymphoblastic leukemia: Indeed, JAK inhibitors (ruxolitinib and tofacitinib) used in patients with rheumatoid arthritis [138] and myelofibrosis [139] could be repurposed for the treatment of T-ALL cases with documented activation of the IL-7R/JAK/STAT pathway.